Y-Intercept (HK)’s Catalyst Pharmaceutical CPRX Stock Holding History

Y-Intercept (HK)’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59M	Buy	+82,483	New	+$2.43M	0.05%	561
2026 Q1	–	Sell	-43,222	Closed	-$1.01M	–	1625
2025 Q4	$1.01M	Sell	43,222 -122,274	-74%	-$2.72M	0.02%	978
2025 Q3	$3.26M	Buy	165,496 +152,925	+1,216%	+$3.14M	0.08%	367
2025 Q2	$273K	Buy	+12,571	New	+$297K	0.01%	1384
2025 Q1	–	Sell	-27,836	Closed	-$581K	–	1258
2024 Q4	$581K	Buy	+27,836	New	+$598K	0.04%	662
2024 Q3	–	Sell	-40,174	Closed	-$622K	–	1386
2024 Q2	$622K	Buy	40,174 +23,792	+145%	+$370K	0.03%	725
2024 Q1	$261K	Buy	16,382 +4,820	+42%	+$72.6K	0.02%	1020
2023 Q4	$194K	Sell	11,562 -46,012	-80%	-$629K	0.02%	1013
2023 Q3	$673K	Buy	+57,574	New	+$770K	0.07%	453
2022 Q3	–	Sell	-18,563	Closed	-$130K	–	1014
2022 Q2	$130K	Buy	+18,563	New	+$136K	0.02%	709

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Y-Intercept (HK)'s CPRX Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 82,483 shares worth $2.59M. The stake represents 0.05% of the portfolio and ranks #561 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CPRX as recently as Q4 2025.

Y-Intercept (HK) first reported a position in CPRX in Q2 2022 and has held it in 10 quarters since. The position peaked at $3.26M in Q3 2025. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Y-Intercept (HK) held 82,483 shares of Catalyst Pharmaceutical worth $2.59M as of Q2 2026.
Catalyst Pharmaceutical was a new Y-Intercept (HK) position in Q2 2026.
Catalyst Pharmaceutical made up 0.05% of Y-Intercept (HK)'s portfolio in Q2 2026, its #561 holding.
Y-Intercept (HK) first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 10 quarters since.
Y-Intercept (HK)'s Catalyst Pharmaceutical position peaked at $3.26M in Q3 2025.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.